For the quarter ending 2025-09-30, SPRY had $8,017K increase in cash & cash equivalents over the period. -$47,244K in free cash flow.
| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Total revenue | 32,501 | - |
| Total segment operating expenses | 85,693 | - |
| Loss from operations | -53,192 | - |
| Other income, net | 2,041 | - |
| Net loss | -51,151 | -78,823 |
| Stock-based compensation expense | 5,689 | 10,669 |
| Depreciation and amortization expense | 391 | 559 |
| Accretion on investments, net of amortization | 1,092 | 3,428 |
| Provision for inventory reserve | 0 | 2,160 |
| Other non-cash items | -186 | - |
| Accounts receivable | 14,007 | 14,375 |
| Inventories | -963 | 13,232 |
| Prepaid expenses and other assets | -1,069 | 697 |
| Donation of equipment | 0 | 0 |
| Accounts payable and accrued liabilities | 10,964 | 16,981 |
| Operating lease right-of-use asset and lease liability, net | -4 | 92 |
| Contract liability | -55 | -240 |
| Net cash and cash equivalents used in operating activities | -47,047 | -80,334 |
| Purchases of short-term investments, available-for-sale | 127,424 | 65,723 |
| Maturities of short-term investments, available-for-sale | 88,500 | 143,500 |
| Payments of milestone obligations under license agreements | 5,860 | - |
| Purchases of property and equipment | 197 | 142 |
| Net cash and cash equivalents provided by (used in) investing activities | -44,981 | 77,635 |
| Proceeds from term loan, net of issuance costs | 97,750 | - |
| Payment of term loan issuance costs to third parties | 761 | - |
| Proceeds from milestone obligations met under license agreements recognized as an increase to the financing liability | 2,577 | - |
| Proceeds from exercise of common stock options and issuance of common stock under the employee stock purchase plan | 479 | 3,422 |
| Net cash and cash equivalents provided by financing activities | 100,045 | 3,422 |
| Net increase (decrease) in cash and cash equivalents | 8,017 | 723 |
| Cash and cash equivalents at beginning of period | 50,817 | - |
| Cash and cash equivalents at end of period | 59,557 | - |
ARS Pharmaceuticals, Inc. (SPRY)
ARS Pharmaceuticals, Inc. (SPRY)